Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS
Status:
Completed
Trial end date:
2011-09-30
Target enrollment:
Participant gender:
Summary
The purpose of the assay is to assess the safety and the efficacy of TRO19622 330 mg QD as
add-on therapy to riluzole 50 mg bid in the treatment of patients suffering from ALS, as
compared to placebo, assessed by the 18-month survival rate.